HRMY — Harmony Biosciences Holdings, Inc.

Harmony Biosciences Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $261.3 million, a 30% increase year-over-year and a 21% increase from Q1 2026.
• Net Income: $75.4 million, or $1.28 per diluted share, compared to $39.8 million, or $0.68 per diluted share in the prior year.
• Cash Position: $962.5 million in cash, cash equivalents, and investments, with $155 million in debt.
• Cost of Goods Sold: Increased to 24.2% of net revenue from 19% year-over-year, primarily due to new royalties from a licensing agreement.

2. Strategic Updates and Business Highlights

• WAKIX Performance: Achieved record quarterly revenue, on track to exceed $1 billion in net revenue for 2026, supported by a strong patient addition of 8,950, marking the highest Q2 increase in the brand's history.
• Pipeline Development: Positive Phase I data for BP-205, a potential best-in-class orexin-2 receptor agonist, with plans for Phase II trials to begin mid-2027.
• Business Development: Focus on strategic acquisitions and partnerships, leveraging a strong balance sheet to explore opportunities in CNS indications, including narcolepsy and broader CNS disorders.
• IP Strategy: Multilayered patent estate supports WAKIX exclusivity until March 2030, with potential extensions into the 2040s.

3. Forward Guidance and Outlook

• Revenue Guidance: Reiterated full-year guidance of $1 billion to $1.04 billion in net revenue for 2026.
• Data Catalysts: Anticipated top-line data from multiple studies for BP-205 in the next 6 months, including a multiple ascending dose study in Q4 2026 and a Phase Ib study in sleep-deprived healthy volunteers in early 2027.

4. Bad News, Challenges, or Points of Concern

• Cost Increases: Rising cost of goods sold due to new royalties could impact margins.
• Regulatory and Competitive Risks: Potential challenges from ongoing litigation with ANDA filers and competition from other orexin-2 receptor agonists in development.
• Market Dynamics: Although patient additions are strong, the overall market for narcolepsy treatments remains competitive, with ongoing pressures from new entrants.

5. Notable Q&A Insights

• BP-205 Profile: Discussion on the potential differentiated clinical profile of BP-205, emphasizing its rapid Tmax, long half-life, and high potency, which may provide advantages in efficacy and safety compared to existing treatments.
• Selectivity and Potency: BP-205 demonstrates over 600-fold selectivity for orexin-2 receptors, which is expected to minimize adverse events associated with orexin-1 receptor activation.
• Commercial Strategy: Harmony is prepared to expand into broader CNS indications, leveraging existing commercial infrastructure and expertise, despite the challenges of entering larger, more competitive markets.
• Patient Addition Trends: Continued strong growth in patient additions for WAKIX is expected to persist through the remainder of the year, maintaining momentum from Q2.

This summary encapsulates the key aspects of Harmony Biosciences' Q2 2026 earnings call, highlighting financial performance, strategic initiatives, outlook, and notable insights from the Q&A session.